Skip to main content

Table 2 Changes operated on clinical and laboratory parameters after anti-TNFα/DMARDs treatment in responder and non-responder RA patients

From: Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα

 

Responders (N = 85)

Non-responders (N = 10)

 

Before anti-TNF treatment

After anti-TNF treatment

P

Before anti-TNF treatment

After anti-TNF treatment

P

Clinical assessments

      

TJC

15.9 ± 4.8

5.1 ± 2.2

0.000

15.6 ± 5.1

8.5 ± 2.9

0.005

SJC

11.7 ± 3.9

2.9 ± 1.8

0.000

11.6 ± 4.9

5.1 ± 2.7

0.005

DAS28

5.8 ± 0.6

3.3 ± 0.7

0.000

5.5 ± 0.7

4.3 ± 0.6

0.005

SDAI

36.3 ± 11.4

2.9 ± 6.8

0.000

39.2 ± 11.8

5.7 ± 12.1

0.005

HAQ

2.1 ± 0.3

1 ± 0.4

0.000

2.1 ± 0.3

1 ± 0.3

0.008

Serological assessments

      

ESR (mm/h)

56.4 ± 17.2

27.9 ± 18.5

0.000

51.4 ± 11.9

37.6 ± 19.3

ns

CRP (mg/L)

3.9 ± 2.1

1.5 ± 1.2

0.000

2.2 ± 0.8

2.5 ± 0.9

ns

RF (U/L)

155.2 ± 288.3

85.4 ± 241

0.000

61.2 ± 84.3

20.8 ± 39.9

0.027

IL-6 (pg/mL)

9.4 ± 46.7

1.4 ± 6.8

0.000

2.1 ± 5.6

0

ns

TNF (pg/mL)

14.9 ± 28.8

5.7 ± 6.1

0.038

4.1 ± 4.5

4.7 ± 5.1

ns

sTNFRII (pg/mL)

1.5 ± 0.9

1.5 ± 0.7

ns

1.3 ± 0.4

1.5 ± 0.7

ns

MCP-1 (pg/mL)

1174.8 ± 1615.4

1216.4 ± 1655.4

ns

740 ± 504.6

678.6 ± 221.8

ns

VEGF (pg/mL)

1107.7 ± 1360.9

830.3 ± 570.1

ns

796.7 ± 462.7

1077.9 ± 711.6

ns

IL23 (pg/mL)

115 ± 235.5

76.8 ± 132.9

ns

41.2 ± 30.5

223.5 ± 424.8

ns

IL22 (pg/mL)

46.3 ± 112

17.2 ± 29.2

ns

8.4 ± 8.1

104.9 ± 193.3

ns

IL17 (pg/mL)

4.8 ± 8.5

2.1 ± 2.1

0.024

11.9 ± 19.1

1.4 ± 1.4

ns

IL4 (pg/mL)

22.8 ± 17.6

14.9 ± 16.2

ns

4.2 ± 6

12.8 ± 18.2

ns

  1. TNFα, tumor necrosis factor alpha; DMARDS, disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; T1 baseline; T2 at 6 months; TJC, tender joint count; SJC, swollen joint count; DAS28, disease activity score; SDAI, simplified disease activity index; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; IL-6, interleukin 6; TNF, tumor necrosis factor; sTNFRII, soluble tumor necrosis factor receptor type II; MCP-1, monocyte chemoattractant protein 1; VEGF, vascular endothelial growth factor; IL-23, interleukin 23; IL-22, interleukin 22; IL-17, interleukin 17; IL-4, interleukin 4.